BridgeBio Pharma, Inc. (BBIO) Form 8-K — Aug 17, 2026
BridgeBio Pharma entered an underwriting agreement on August 13, 2026 for a secondary offering of 5,000,000 shares of its common stock sold entirely by existing holder KKR Genetic Disorder L.P. at a price to the public of $78.00 per share, with William Blair, Goldman Sachs and KKR Capital Markets acting as joint book-running managers. The underwriters purchased the shares at $77.415 each, a $0.585 per-share discount, implying roughly $390 million in gross proceeds to the selling stockholder; the sale was expected to close on August 17, 2026 under BridgeBio's automatic shelf registration on Form S-3ASR.
Key figures
- Offering Price
- 78
- Shares Offered
- 5000000
- Company proceeds
- 0
- Lockup period days
- 30
- Expected closing date
- 2026-08-17
- Shares registered under shelf
- 24628286
- Underwriting discount per share
- 0.585
- Underwriter purchase price per share
- 77.415
Price after filing
Close on the filing date to close N calendar days later (from $79.89). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.